Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Visual and Neural Responses to Naked-Eye 3-D Viewing

27 de setembro de 2026 atualizado por: Jinyuan,MD, Beijing Tongren Hospital

Multimodal Ocular and Neural Responses to Naked-Eye 3-D Display Exposure: A Prospective Self-Controlled Study

This multicenter study examines short-term changes in visual fatigue and eye function after glasses-free three-dimensional (3D) viewing in healthy adults. The study is conducted at Zhongshan Ophthalmic Center in Guangzhou and Beijing Tongren Hospital in Beijing. Participants complete assessments immediately before and after a 30-minute 3D viewing session and serve as their own controls. The main outcome is the change in self-reported visual fatigue score. Other assessments, according to the procedures approved at each site, may include eye and binocular vision tests, symptom questionnaires, and electroencephalography (EEG). Where approved, additional viewing sessions examine different display settings, including binocular disparity and image crosstalk.

Visão geral do estudo

Status

Concluído

Intervenção / Tratamento

Descrição detalhada

Glasses-free 3D displays create a perception of depth without requiring 3D glasses. Viewing these displays may place demands on binocular vision and visual comfort. This study evaluates immediate responses to a standardized viewing session using subjective ratings and clinical measurements.

This is a multicenter, self-controlled study at Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China, and Beijing Tongren Hospital, Capital Medical University, Beijing, China. Eligible adults provide written informed consent before any study procedures. Each participant completes assessments immediately before viewing standardized glasses-free 3D content for 30 minutes and immediately after viewing.

The primary outcome is the within-participant change in current visual fatigue score, rated on a 0-to-3 scale, from before to after the viewing session. Secondary assessments may include tear film stability, accommodation, ocular alignment, other binocular vision measures, subjective symptoms, and EEG measures, as specified in the applicable site-approved protocol. At sites where additional sessions are approved, predefined display settings may be used to examine responses to different levels of binocular disparity or image crosstalk.

Participants may pause or stop viewing if they experience discomfort. Study staff record symptoms and interruptions during the session. Analyses will describe within-participant changes and account for differences between study sites where combined analysis is appropriate.

Tipo de estudo

Intervencional

Inscrição (Real)

150

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Beijing, China
        • Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Intelligent Diagnosis Technology and Equipment for Optic Nerve-Related Eye Diseases, National Engineering Research Center for Ophthalmology

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 40 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age ranges 18-40 years old at the time of screening.
  • Best-corrected visual acuity ≥0.8 in both eyes.
  • Normal stereopsis confirmed via clinical stereo test.
  • Spherical equivalent refractive error between -6.00 diopters and +3.00 diopters.
  • Astigmatism ≤2.00 D and no clinically significant anisometropia.
  • No history of ocular surgery, eye disease, neurological disorder, mental illness or cognitive impairment that affects visual performance.
  • Able to understand study procedures and finish all ophthalmological and electroencephalogram examinations.
  • Voluntarily provides written informed consent before any study-related operation.

Exclusion Criteria:

  • Younger than 18 years or older than 40 years.
  • Best-corrected visual acuity less than 0.8 in either eye.
  • Impaired or abnormal stereoscopic vision.
  • Unqualified refractive error, obvious anisometropia.
  • History of keratitis, glaucoma, retinal disease and other organic eye diseases.
  • Any history of corneal or intraocular surgery.
  • Systemic disease, brain disease and psychiatric disease interfering with visual function.
  • 1. Refuses or cannot complete all three sub-experiment sessions and repeated multimodal tests.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: Naked-Eye 3D Visual Exposure Arm

Participants view standardized glasses-free 3D content for 30 minutes. Visual fatigue and other approved outcomes are assessed immediately before and after viewing. Where specified in the site-approved protocol, participants may complete additional sessions with predefined binocular disparity or image crosstalk settings.

Participants view standardized content on a glasses-free 3D display for 30 minutes per session. The display, viewing distance, content, and environmental conditions are documented. Additional sessions using predefined binocular disparity or image crosstalk settings are conducted only where included in the approved study procedures.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Simulator Sickness Questionnaire (SSQ) Score
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Validated Simulator Sickness Questionnaire (SSQ). A higher score represents stronger perceived visual burden induced by stereoscopic display. The continuous numeric SSQ scores obtained pre- and post-exposure will be compared by means of a paired-samples t-test, provided that the normality assumption is satisfied; otherwise, the non-parametric Wilcoxon signed-rank test will be adopted.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in accommodative response (Diopters)
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Paired comparison of accommodative response value before and after stereoscopic exposure to assess accommodation adaptation induced by naked-eye 3D display.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Change in distance phoria (prism diopters)
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Quantify pre-post shift of far-distance binocular alignment after naked-eye 3D viewing.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Change in near phoria (prism diopters)
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Evaluate alteration of near binocular alignment before and after stereoscopic visual exposure.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Change in accommodative convergence/accommodation (AC/A) ratio
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Detect pre-post variation of AC/A ratio reflecting binocular coordination adaptation under 3D stimulation.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Change in non-invasive tear break-up time (seconds)
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Compare pre-post tear film stability to evaluate ocular surface burden from prolonged 3D viewing.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Change in best-corrected visual acuity (LogMAR)
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Assess transient fluctuation of corrected visual acuity after naked-eye 3D exposure.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Change in intraocular pressure (mmHg)
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Measure pre-post intraocular pressure variation following stereoscopic viewing.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Change in near stereoacuity
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Detect alteration of depth perception ability before and after naked-eye 3D stimulation.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Spectral amplitude of theta, alpha, beta and gamma EEG frequency bands
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Compare pre-post power amplitude of four core brain wave bands to reflect cortical activation changes.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Change in gamma-band resting-state functional connectivity strength
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Evaluate alteration of high-frequency neural synchronization across visual cortex induced by stereoscopic viewing.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
P300 event-related potential peak amplitude (standard stimulus)
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Pre-post comparison of P300 amplitude under standard visual stimuli to quantify attentional cortical processing.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
P300 event-related potential peak latency (standard stimulus)
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Detect shift of P300 response latency before and after naked-eye 3D exposure.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
P300 peak amplitude and latency under deviant visual stimulus
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Assess change of cognitive ERP response to oddball deviant stimuli after stereoscopic viewing.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Change in PANAS positive and negative affect scores
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Evaluate fluctuation of positive and negative emotional states after stereoscopic visual exposure.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing
Change in state anxiety scale (SAS) total score
Prazo: baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Detect transient anxiety level variation before and after naked-eye 3D viewing.

baseline (pre-exposure), immediately after 30-minute naked-eye 3-D viewing

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Diagnostic performance of multimodal visual fatigue risk prediction model
Prazo: through study completion, an average of 1 year

Multivariable logistic regression model combining baseline phoria and theta-band EEG features; evaluate model discrimination via AUC-ROC, overall accuracy, sensitivity and specificity for identifying participants at high risk of severe post-exposure visual fatigue.

through study completion, an average of 1 year

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de dezembro de 2024

Conclusão Primária (Real)

20 de setembro de 2026

Conclusão do estudo (Real)

20 de setembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

9 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

27 de setembro de 2026

Primeira postagem (Real)

30 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

30 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 2024KYPJ139

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared with external researchers under the current study plan. Participant-level ophthalmic, questionnaire, and EEG data are held by the participating institutions and managed in accordance with the approved consent and institutional data governance requirements. Aggregate results may be reported in publications.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever